Melanoma Advanced Locally unresectable | Metastatic melanoma unresectable | Squamous cell carcinoma of the head and neck | Non-Small Cell Lung Carcinoma CD276 gene Expression
Item
histologically-proven, unresectable, locally advanced or metastatic melanoma, scchn, or nsclc that express b7-h3.
boolean
C0025202 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C1517927 (UMLS CUI [1,3])
C1519810 (UMLS CUI [1,4])
C0278883 (UMLS CUI [2,1])
C1519810 (UMLS CUI [2,2])
C1168401 (UMLS CUI [3])
C0007131 (UMLS CUI [4,1])
C1540293 (UMLS CUI [4,2])
C0017262 (UMLS CUI [4,3])
Melanoma Progressive | Disease Progression | Other Coding | Anti-PD-L1 | Anti-PD1 | Anti-CTLA-4 | Prior Therapy
Item
melanoma that has progressed within 90 days with progression on a checkpoint inhibitor (e.g., anti-pd-l1, anti-pd-1, anti-ctla-4) as the most recent prior therapy
boolean
C0025202 (UMLS CUI [1,1])
C0205329 (UMLS CUI [1,2])
C0242656 (UMLS CUI [2])
C3846158 (UMLS CUI [3])
C4289971 (UMLS CUI [4])
C4289970 (UMLS CUI [5])
C4289973 (UMLS CUI [6])
C1514463 (UMLS CUI [7])
Squamous cell carcinoma of the head and neck | Non-Small Cell Lung Carcinoma | Disease Progression Following Systemic therapy
Item
schnn or nsclc that has progressed during or following 1 - 5 prior systemic regimens
boolean
C1168401 (UMLS CUI [1])
C0007131 (UMLS CUI [2])
C0242656 (UMLS CUI [3,1])
C0332282 (UMLS CUI [3,2])
C1515119 (UMLS CUI [3,3])
Measurable Disease
Item
measurable disease per recist 1.1 criteria
boolean
C1513041 (UMLS CUI [1])
ECOG performance status
Item
ecog performance status 0 or 1
boolean
C1520224 (UMLS CUI [1])
Laboratory Results Acceptable | Organ function Mass
Item
acceptable laboratory parameters and adequate organ reserve.
boolean
C1254595 (UMLS CUI [1,1])
C1879533 (UMLS CUI [1,2])
C0678852 (UMLS CUI [2,1])
C1306372 (UMLS CUI [2,2])
CNS metastases Symptomatic | Exception CNS metastases Treated | Exception CNS metastases Asymptomatic
Item
patients with a history of symptomatic central nervous system metastases, unless treated and asymptomatic
boolean
C0686377 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0686377 (UMLS CUI [2,2])
C1522326 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0686377 (UMLS CUI [3,2])
C0231221 (UMLS CUI [3,3])
Autoimmune Disease
Item
patients with history of autoimmune disease with certain exceptions
boolean
C0004364 (UMLS CUI [1])
Allogeneic bone marrow transplantation | Stem cell transplant | Solid organ transplant
Item
history of allogeneic bone marrow, stem cell, or solid organ transplant
boolean
C0149615 (UMLS CUI [1])
C1504389 (UMLS CUI [2])
C0730400 (UMLS CUI [3])
Cancer treatment Systemic | Therapy, Investigational | Therapeutic radiology procedure | Trauma Surgery | Major surgery
Item
treatment with systemic cancer therapy or investigational therapy within 4 weeks; radiation within 2 weeks; trauma or major surgery within 4 weeks
boolean
C0920425 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C0949266 (UMLS CUI [2])
C1522449 (UMLS CUI [3])
C3714660 (UMLS CUI [4,1])
C0543467 (UMLS CUI [4,2])
C0679637 (UMLS CUI [5])
Cardiovascular Disease | Gastrointestinal perforation | Gastrointestinal Hemorrhage | Pancreatitis | Diverticulitis
Item
history of clinically-significant cardiovascular disease; gastrointestinal perforation; gastrointestinal bleeding, acute pancreatitis or diverticulitis within 4 weeks;
boolean
C0007222 (UMLS CUI [1])
C0151664 (UMLS CUI [2])
C0017181 (UMLS CUI [3])
C0030305 (UMLS CUI [4])
C0012813 (UMLS CUI [5])
Virus Disease | Bacterial Infection | Systemic mycosis | Requirement Parenteral therapy | HIV Seropositivity | Hepatitis B positive | Hepatitis C positive
Item
active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days; positive for human immunodeficiency virus or aids, hepatitis b or c.
boolean
C0042769 (UMLS CUI [1])
C0004623 (UMLS CUI [2])
C0553576 (UMLS CUI [3])
C1514873 (UMLS CUI [4,1])
C0259961 (UMLS CUI [4,2])
C0019699 (UMLS CUI [5])
C0856706 (UMLS CUI [6])
C1112419 (UMLS CUI [7])
Hypersensitivity Recombinant Proteins | Hypersensitivity Polysorbate 80 | Hypersensitivity Excipient MGA271 | Hypersensitivity Excipient Ipilimumab
Item
known hypersensitivity to recombinant proteins, polysorbate 80, or any excipient contained in the drug or vehicle formulation for mga271 or ipilimumab.
boolean
C0020517 (UMLS CUI [1,1])
C0034861 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0032601 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0015237 (UMLS CUI [3,2])
C3273458 (UMLS CUI [3,3])
C0020517 (UMLS CUI [4,1])
C0015237 (UMLS CUI [4,2])
C1367202 (UMLS CUI [4,3])